The Scientific Foundations of AI-Enabled Discovery
AI is changing more than the tools of biomedical research—it is changing the way discovery itself is done. This keynote will examine the scientific foundations needed to make AI-enabled discovery rigorous, reproducible, and translatable, with a focus on methods, infrastructure, and interdisciplinary collaboration. The talk will highlight how stronger systems for research design and validation can help move AI from promising innovation to meaningful clinical and scientific impact.
 

Turning AI Research into AI Action
AI holds enormous promise to improve patient care—but only if it moves beyond research and into everyday clinical practice. Today, the greatest challenge is not developing AI, but ensuring it is safely implemented, trusted by clinicians, and meaningfully integrated into care delivery. This session will explore how healthcare organizations can accelerate the adoption of clinical AI while maintaining a focus on safety, trust, and the human connection to deliver better patient outcomes.
 

From Discovery to Deployment: How AI Creates Enterprise Impact
This panel will explore how AI delivers value when discovery, translation, and deployment are treated as parts of a connected enterprise system rather than isolated activities. The discussion will examine how research priorities, governance structures, and operational alignment influence whether promising ideas advance from early investigation into scalable clinical and organizational use. Panelists will address common points where AI efforts stall and discuss what distinguishes exploratory work from solutions that are ready for enterprise adoption. The session will highlight governance not as a barrier, but as a mechanism for speed, trust, and consistency. Together, the conversation will offer a practical view of how integrated AI ecosystems help turn innovation into measurable impact.

Dr. Cui Tao, Dr. Micky Tripathi, Dr. Vijay Shah, Matt Redlon, Dr. Cheryl Willman

About three years ago, while ChatGPT and, later, the GPT-4 AI model were still in secret development at OpenAI, a group of Researchers at Microsoft Research started investigating the potential impact of this new technology on healthcare delivery and medical research. One result of this investigation was the publication of the book in early 2023, "The AI Revolution in Medicine: GPT-4 and Beyond," coauthored with Carey Goldberg and Isaac Kohane. But since the book was written while GPT-4 was still a secret to the world, it was largely a work of speculation. So now, with a bit more than two years of real-world observation and experience, what is actually happening, and what is likely to happen next in the world of healthcare? This talk will go into what we had predicted, and what we got right, what we missed, as a way to help us see a bit into the future.

Moderator: Jared Staal
Panelists: 

The potential of artificial intelligence (AI) in medicine is vast, yet its translation into trusted, decision-grade evidence for clinical development and regulatory submission remains a fundamental challenge. We must move beyond theoretical promise to develop a practical blueprint for building an AI-powered evidence engine.

Drawing on real-world case studies, we will demonstrate how integrated, multimodal approaches are actively de-risking programs and accelerating regulatory decisions. We will explore the application of AI-driven disease progression models to enhance trial design, the development of purpose-built AI tools that democratize advanced analytics, and the strategic use of patient digital twins to guide development decisions. The discussion will extend to critical regulatory partnerships, including an FDA research collaboration to address RW disease outcome measurement, and the practical implications of emerging FDA guidance on AI.

The true evolution lies not in any single model, but in systematically integrating advanced patient modeling, causal reasoning, and pragmatic AI to create a new tier of evidence. This integrated approach ultimately builds clinical and regulatory confidence for us to deliver better, faster decisions for patients.

Panel Moderator: Dr. Michelle McGowan 
Panelists: Dr. Demilade Adedinsewo,  Dr. Imon Banerjee, Dr. Barbara Barry